Cancer-fighting T cells can lose their edge after prolonged exposure to tumors.
New research from Memorial Sloan Kettering Cancer Center suggests one reason may be surprisingly simple: the cells are being pushed to work at an energy level they cannot sustain.
The peer-reviewed study, published online in Immunity on July 13, 2026, focused on CD8+ T cells and the MEK pathway. Researchers found that chronic stimulation increased the cells’ energy demands, increased mitochondrial stress, and pushed them toward terminal exhaustion.
That does not mean scientists have found a new treatment for patients. The work is preclinical, and it does not show that MEK inhibitors improve survival or make immunotherapy work better in people.
The study does provide a closer look at why cancer-fighting T cells can lose function after being kept in a constant state of attack.
The Cells Were Spending Too Much Energy
The researchers found that exhaustion was tied to unusually high energy demand, not simply a lack of fuel.
The paper, titled MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion, examined what happens when T cells are stimulated over long periods.
Persistent T cell receptor signaling increased demand for ATP, which cells use as an immediate energy source. That increase was linked to greater protein synthesis, mitochondrial NADH buildup, reactive oxygen species, and eventual mitochondrial dysfunction.
MEK signaling sat near the center of that process. Sustained MEK activity increased global protein production, adding to the energy burden on the cells.
In Memorial Sloan Kettering press materials, first author Tanmana Mitra said, “It changed how we think about T cell exhaustion, from a problem of too little energy to one of excessive energy demand.”
The researchers also reported changes in RNA polymerase II CTD phosphorylation and in transcription rates at genes tied to effector function and terminal exhaustion. Memory-related genes were comparatively maintained.
Exhaustion Was Not an All-or-Nothing State
Blocking MEK changed the direction the cells were moving in without wiping away every sign of exhaustion.
When the researchers inhibited MEK, T cells showed lower expression of genes associated with effector activity and terminal exhaustion. At the same time, memory-associated programs were preserved, and the cells retained greater proliferative capacity.
Some markers changed while others did not. PD-1 expression remained, while TIM-3 and LAG-3, both associated with more terminal exhaustion, were reduced.
That is an important limitation of the finding. MEK inhibition did not return exhausted T cells to a completely normal state.
Instead, it appeared to influence how far the cells progressed toward terminal exhaustion. That makes the biology less like a simple on-and-off switch and more like a series of states shaped by prolonged stimulation.
Save this article
Enter your email address and we'll send it straight to your inbox.
Preserving T Cells Comes With a Cost
The same pathway linked to exhaustion also supports the machinery T cells use to attack cancer.
MEK activity helps drive protein production involved in the immune response. Reducing that activity can lower metabolic pressure, but it can also reduce some of the cells’ immediate effector activity.
Senior author Santosha A. Vardhana described that balance in Memorial Sloan Kettering press materials: “MEK tells exhausted cells whether to conserve fuel or go for broke.”
That tradeoff is central to the research. Keeping T cells around longer may mean asking them to operate less aggressively in the short term.
The study does not establish which balance would work best in patients. It also does not show that the same approach would work equally well across different cancers or treatment settings.
Related: 10 Simple Habits to Recharge Your Mind and Body
An Existing Drug Target Could Have a New Role
MEK is already targeted by approved cancer drugs, giving researchers a practical pathway for further study.
FDA-approved MEK inhibitors are already used for certain cancer indications. That does not mean they are approved to prevent T cell exhaustion, but it does mean the pathway can already be targeted with existing drugs.
Vardhana said in the same press materials, “FDA approved MEK inhibitors are already available, so this approach could be tested in humans without much delay.”
The wording matters. The study shows a mechanism and a possible intervention point. It does not provide evidence that giving MEK inhibitors to patients for this purpose will improve outcomes.
Researchers have discussed possible relevance to checkpoint inhibitors, CAR T therapy, tumor-infiltrating lymphocyte therapy, and bispecific antibodies. Those uses remain research possibilities, not established treatment strategies.
Human Testing Is Still the Missing Piece
The next major step is finding out whether the same biology can be used safely and effectively in patients.
An earlier version of the research appeared as a bioRxiv preprint dated April 30, 2025. Immunity published the peer-reviewed paper online on July 13, 2026, and later in the journal’s August 11 issue.
The study reports no human response rates, survival data, or validated dosing strategy for using MEK inhibition to preserve T cells. Researchers also do not yet know which cancers would be most suitable, when to give MEK inhibition, or how much reduced short-term activity would be acceptable in exchange for longer T cell persistence.
Cancer immunotherapy has often been built around the idea of pushing immune cells to attack harder. This study suggests that endurance may matter just as much as force.
How might this discovery change the way researchers think about keeping cancer-fighting T cells effective for longer?
